Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their ...

Dexcom’s OTC glucose biosensor Stelo is the first product to use the GenAI platform for improved weekly insights.

Continuous Glucose Monitoring Devices Market was valued at US$ 5.89 Bn in 2024 and is to reach a value of US$ 12.51 Bn by 2031 at a CAGR of 9.9%. BURLINGAME, CA, UNITED STATES, December 12 ...

Abbott Laboratories and DexCom said on Monday they have reached an agreement to settle all patent disputes between them ...

Abbott has announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the ...

The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched ... The diabetes device giant said the first product to receive ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

Bengaluru: Abbott Laboratories and DexCom said on Monday they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) on December 27 and set a price target of $94.00.

Dexcom is a developer and marketer of continuous glucose monitoring (CGM) systems for people with diabetes. The company aims to simply glucose monitoring while incorporating the latest technology to ...